Association between drug intake and incidence of malignancies in patients with Juvenile Idiopathic Arthritis: a nested case–control study. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Barth, Swaantje; Schlichtiger, Jenny; Bisdorff, Betty; Hügle, Boris; Michels, Hartmut; Radon, Katja; Haas, Johannes-Peter
• Is Part Of: Pediatric rheumatology online journal. Volume 14:Issue 1(2016)
• Page Start: 1
• Page End: 6
• Publication Date: 2016-12
• Subjects: Juvenile idiopathic arthritis (JIA) -- Malignancy -- Cancer -- Incidence -- Drug intake -- Biologics -- Tumour necrosis factor α; Pediatric rheumatology -- Periodicals; Rheumatism in children -- Periodicals; 618.92723
• DOI: 10.1186/s12969-016-0066-8
• Languages: English
• ISSNs: 1546-0096

Abstract

Abstract Background Several medications for treatment of Juvenile Idiopathic Arthritis (JIA) are considered to be carcinogenic. Therefore, the aim was to assess whether there is an association between therapeutic interventions and malignancies in JIA patients. Findings A nested case–control study was carried out within a retrospective cohort study of 3698 JIA patients diagnosed between 1952 and 2010. All 48 JIA patients with a diagnosis of a malignant tumour and up to four matched controls for each received a questionnaire about their use of medication. Subsequently treatment was compared between cases and controls and analyses performed for 37 cases and 125 controls (response 88.5 %). Treatment with DMARD (84 %) was most frequently used, followed by glucocorticoids (66 %) and immunosuppressives (65 %). Twenty percent reported to have ever been taking biologics. Medication use did not differ significantly between cases and controls. Conclusions Our results did not show an association between medications used and malignancies in JIA patients.